Company intelligence / Profile preview

Filamon Limited

Ownership: Private
Development stage: Phase 1

Overview

Filamon is developing next-generation anti-inflammatory drugs for chronic degenerative diseases. Their lead candidate ALPHA-003 for dementia is advancing through pre-clinical testing with clinical trials aimed for 2026. They have three drug technology platforms specifically designed to treat complex inflammatory diseases.

Therapeutic areas: OncologyOphthalmologyNeurology
Modalities: Small molecules
Industry: Biotech

Drug pipeline

4 assets

BETA-TT8

3 more assets in the full pipeline.

Request access →

Partnerships

Henry Ford Health (Detroit, Michigan, USA)

Beyond the preview

Go deeper on Filamon Limited.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Filamon Limited.

Explore the full profile